INDEPENDENCE ACE-536-MF-002

About this trial

This Study is to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions.

Patient Profile

Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Where’s this trial being run?

St James’s Hospital and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: INDEPENDENCE ACE-536-MF-002
Number: 20-34
Full Title:

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Principal Investigator: Dr Clodagh Keohane
Type: Industry Sponsored
Sponsor:

Celgene/Bristol-Myers Squibb

Recruitment Started: Global: 11-Mar-21
Ireland: 24-May-21
Global Recruitment Target: Approx. 390 patients
Ireland Recruitment Target: 1-2 patients per site